4138-20-9Relevant academic research and scientific papers
2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
-
Page/Page column 87, (2020/05/28)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
t-Butyl pyridine and phenyl C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists
Lee, Sunho,Kang, Dong Wook,Ryu, HyungChul,Kim, Changhoon,Ann, Jihyae,Lee, Hobin,Kim, Eunhye,Hong, Sunhye,Choi, Sun,Blumberg, Peter M.,Frank-Foltyn, Robert,Bahrenberg, Gregor,Stockhausen, Hannelore,Christoph, Thomas,Lee, Jeewoo
, p. 2451 - 2462 (2017/04/03)
A series of 2-substituted 6-t-butylpyridine and 4-t-butylphenyl C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The analysis of structure activity relationships indicated that the pyridine
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
Page/Page column 685-686, (2021/02/10)
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
-
Paragraph 1808; 1809, (2016/05/02)
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
NOVEL BRONCHODILATING DIAZAHETEROARYLS
-
Page/Page column 71-72, (2012/03/08)
The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.
NOVEL BRONCHODILATING DIAZAHETEROARYLS
-
Page/Page column 151, (2010/09/17)
The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.
NEW COMPOUNDS III
-
Page/Page column 35, (2008/06/13)
The present invention relates to new compounds [Chemical formula should be inserted here. Please see paper copy] (I) or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, ph
